Gilead’s $4.3B Bet on CymaBay’s Liver Drug
Gilead Sciences plans to acquire CymaBay Therapeutics for $4.3 billion, expanding their liver disease portfolio. The deal is expected to ...
- Latest
- Trending
Gilead Sciences plans to acquire CymaBay Therapeutics for $4.3 billion, expanding their liver disease portfolio. The deal is expected to ...
Intuitive Machines' stock soars as it prepares for a historic moon mission. A successful landing would be a major achievement ...
InterDigital appoints Ken Kaskoun as Chief Growth Officer to drive expansion in mobile and AI technology. The appointment strengthens InterDigital's ...
Anixa Biosciences advances Phase 1 clinical trial for ovarian cancer therapy, increasing dosage and showing promising results. Market responds positively ...
Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to expand its liver disease portfolio, including access to potential treatment for ...
Truist Securities raises price target for Shopify shares ahead of earnings report, predicting strong growth potential. Market sentiment is positive.
Novo Nordisk sees massive sales jump and expects further growth in 2024, driven by the demand for its diabetes and ...
Oppenheimer lowers price target on Gilead Sciences after Q4 earnings report and challenges in drug pipeline. Optimistic about prospects for ...
Turkey's first astronaut, Alper Gezeravci, successfully completes a 3-week mission to the International Space Station, showcasing the country's growing aerospace ...
China is facing a shortage of finance professionals with expertise in ESG issues, according to a report by the CFA ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.